Benzodiazepines in older adults

Drug-class library

Benzodiazepines have the clearest harm signal of any class reviewed in older adults, and also the best-tested method for discontinuing them. Both halves of that sentence matter.

What changes with age

The same dose does more. Clearance falls, the volume of distribution for lipid-soluble drugs rises, and the central nervous system becomes more sensitive to the same plasma concentration. A dose that was appropriate at 55 is a different drug at 82.

The harms, with their populations

Fracture

A meta-analysis of 33 observational studies covering 169,660 hip-fracture cases found benzodiazepine users had a relative risk of hip fracture of 1.34 (95% CI 1.26 to 1.44) versus non-users, rising to 1.83 (95% CI 1.46 to 2.28) in current users, with no elevated risk in past users. A separate systematic review found risk greatest in newly prescribed patients — short-term use relative risk 2.40.

That pattern — risk in current and especially new users, absent in past users — is the single most useful thing to know about this class.

Falls in the nursing home, measured directly

A case-crossover study of 594 long-stay US nursing home residents, mean age 87.5, found fall risk approximately 3.8 times higher in the 24 hours after a benzodiazepine was started (odds ratio 3.79, 95% CI 1.10 to 13.00), and that stopping a benzodiazepine was associated with reduced fall risk (odds ratio 0.26, 95% CI 0.08 to 0.91). The confidence intervals are wide and the study is observational.

Cognition and psychomotor function

A meta-analysis of 24 randomized trials covering 2,417 adults aged 60 and over with insomnia found sedative-hypnotics produced small sleep gains — total sleep time increased by 25.2 minutes, sleep-quality effect size 0.14 — while adverse cognitive events were 4.78 times more common (95% CI 1.47 to 15.47), adverse psychomotor events 2.61 times (95% CI 1.12 to 6.09), and daytime fatigue 3.82 times (95% CI 1.88 to 7.80). The authors concluded the benefits “may not justify the increased risk” in people over 60.

Delirium

A systematic review of 14 prospective studies found benzodiazepines associated with 3.0-fold increased odds of delirium (95% CI 1.3 to 6.8) in older adults at risk, and recommended avoiding new prescriptions or considering reduction where possible.

Driving — the finding most often overstated

A meta-analysis of 21 epidemiological and 69 experimental studies found benzodiazepines increase traffic accident risk overall (pooled case-control odds ratio 1.59, cohort incidence rate ratio 1.81), rising sharply with alcohol (odds ratio 7.69). But in subgroup analysis the crash risk was lower in drivers over 65 (pooled odds ratio 1.13, 95% CI 0.97 to 1.31 — not statistically significant) than in drivers under 65 (2.21, 95% CI 1.31 to 3.73), most likely reflecting exposure rather than pharmacology. Anyone citing crash risk in an older-adult context should not claim a larger effect in seniors.

The dementia question, honestly

This is genuinely contested, and the disagreement has a specific shape worth understanding: it is about reverse causation, not about whether an association exists.

Studies reporting increased risk

A nested case-control study of 1,796 Quebec residents over 66 with a first Alzheimer diagnosis, matched to 7,184 controls, found ever-use adjusted odds ratio 1.51 (95% CI 1.36 to 1.69), 1.43 after adjustment for anxiety, depression and insomnia, with a dose-response: no association below 91 prescribed daily doses, 1.32 at 91 to 180, and 1.84 above 180. Its own authors noted benzodiazepine use “might also be an early marker of a condition associated with an increased risk of dementia.” A meta-analysis of 10 observational studies reported a pooled relative risk of 1.51 (95% CI 1.17 to 1.95).

Studies that did not replicate a causal association

• A prospective cohort of 3,434 dementia-free adults aged 65 and over, followed a mean of 7.3 years with 797 developing dementia, found hazard ratios of 1.25 at low exposure, 1.31 at moderate — and 1.07 (95% CI 0.82 to 1.39) at the highest exposure. A dose-response that reverses at the top is not what causation looks like. The authors: “These results do not support a causal association between benzodiazepine use and dementia.”
• A nested case-control study of 26,459 UK patients aged 65 and over demonstrated the mechanism directly. Starting a benzodiazepine less than a year before diagnosis gave adjusted odds ratios of 2.20 for Alzheimer disease and 3.30 for vascular dementia — but initiation 2 to 3 years before gave 0.99 (95% CI 0.84 to 1.17). After accounting for a prodromal phase, long-term use was not associated with dementia at all.
• A Danish nationwide cohort of 235,465 patients found no association after adjustment, with the highest users showing the lowest odds.

The honest statement: the association is real and reproducible; causation is not established; and the strongest counter-evidence is that the dose-response reverses at high exposure and the association collapses once a prodromal window is excluded. That is a sufficient reason for care with this class on its own — the falls, fracture and delirium evidence is not contested and does not depend on the dementia question at all.

Prevalence

Among US adults aged 18 to 80 filling at least one benzodiazepine prescription in 2008, prevalence rose with age to 8.7% in ages 65 to 80, and the proportion of that use which was long-term — 120 days or more — rose to 31.4% in that age group against 14.7% in ages 18 to 35. Only 5.7% of users aged 65 to 80 received the prescription from a psychiatrist. Those are 2008 data; use them for the pattern, not the current rate.

Benzodiazepine prescribing at older-adult primary care visits rose from 5.6% to 8.7% between 2003–2005 and 2010–2012, with growth concentrated among patients with no mental health or pain diagnosis. In US long-stay nursing homes, short-acting benzodiazepine use declined from 12.1% in 2016 to 10.6% in 2018 while long-acting use stayed flat at around 4%, defined as a prescription for at least 30 days in the quarter.

Discontinuation — the best-tested intervention in this whole field

EMPOWER

A cluster randomized trial of 303 community-dwelling long-term benzodiazepine users aged 65 to 95, recruited from 30 Quebec community pharmacies. The intervention was a deprescribing booklet describing the risks plus a stepwise tapering protocol — mailed to the patient, not the prescriber.

At six months, 27% of the intervention group had discontinued against 5% of controls (risk difference 23%, 95% CI 14% to 32%; number needed to treat 4), with dose reduction in a further 11%. 62% of recipients started a conversation about stopping with their physician or pharmacist. Age over 80, sex, duration of use, dose, prior taper attempt and polypharmacy showed no significant interaction — it worked across subgroups. The authors’ framing: “Direct-to-consumer education effectively elicits shared decision making.”

D-PRESCRIBE

A cluster randomized trial of 489 community-dwelling adults aged 65 and over, mean age 75, from 69 Quebec pharmacies. The design is the point: the pharmacist sent the patient an educational brochure in parallel with sending the physician an evidence-based pharmaceutical opinion. Neither acted alone.

At six months, 43% of the intervention group no longer filled the inappropriate prescription against 12% of controls. For the sedative-hypnotic subgroup specifically, 43.2% (63 of 146) against 9.0% (14 of 155).

And the finding that has to be reported alongside it: 29 of 77 patients (38%) who attempted to taper a sedative-hypnotic reported withdrawal symptoms, though no adverse event required hospitalization. That is why this is a supervised process with follow-up rather than a leaflet.

Why tapering is not optional

On September 23, 2020 the FDA required an updated boxed warning across the entire benzodiazepine class. Its language: “Physical dependence can occur when benzodiazepines are taken steadily for several days to weeks, even as prescribed. Stopping them abruptly or reducing the dosage too quickly can result in withdrawal reactions, including seizures, which can be life-threatening.”

And on how to do it: “To reduce the risk of acute withdrawal reactions, use a gradual taper to reduce the dosage or to discontinue benzodiazepines. No standard benzodiazepine tapering schedule is suitable for all patients; therefore, create a patient-specific plan to gradually reduce the dosage, and ensure ongoing monitoring and support as needed.”

The guideline

The 2018 Canadian evidence-based guideline on deprescribing benzodiazepine receptor agonists recommends that deprescribing — tapering slowly — be offered to adults aged 65 and over taking these drugs, regardless of duration of use, and suggests it be offered to adults 18 to 64 who have used them for more than four weeks.

Its scope limit is as important as its recommendation and is reproduced here because it is what keeps this from being blanket advice: the guideline applies to primary insomnia, or comorbid insomnia where the underlying condition is effectively managed. It explicitly does not apply to people with other sleep disorders, or with untreated anxiety, depression, or other physical or mental health conditions that might be causing or aggravating the insomnia.

On method: “Tapering BZRAs improves cessation rates compared with usual care without serious harms.” On approach: “Patients might be more amenable to deprescribing conversations if they understand the rationale (potential for harm), are involved in developing the tapering plan, and are offered behavioural advice.”

What replaces it

For insomnia, something with better evidence than the drug. The American College of Physicians gives cognitive behavioral therapy for insomnia a strong recommendation as initial treatment for all adults with chronic insomnia; drug therapy gets a weak, second-line, short-term recommendation. What replaces the medication.

Common questions

Do benzodiazepines cause dementia?

The association is real and reproducible; causation is not established. Two large studies found the dose-response reverses or disappears at highest exposure, and a third found the association collapses once a prodromal window is excluded — consistent with these drugs being prescribed for the early symptoms of dementia rather than causing it. The falls, fracture and delirium evidence is not contested and is reason enough for care. The evidence base.

Can someone who has taken these for twenty years stop?

The randomized evidence says a substantial proportion can, with a slow taper and support — and that duration of use did not predict success in the EMPOWER trial. It has to be gradual and supervised: the FDA warns that abrupt cessation can cause withdrawal reactions including seizures, and 38% of people attempting a sedative-hypnotic taper in one trial reported withdrawal symptoms. Tapering principles.

What if the benzodiazepine is for anxiety, not sleep?

Then the deprescribing guideline explicitly does not apply. It covers primary insomnia, or comorbid insomnia where the underlying condition is effectively managed, and states that it does not apply where anxiety or depression is untreated. That boundary matters, and it is why a decision belongs to the prescriber who knows the whole picture. The medication review.

Back to the drug-class library.

Memory: this is mechanism, not a side effect

Benzodiazepines impair the formation of new memories while they are being taken. This is not a contested trial outcome and it does not need hedging — it is how the drugs work.

They are positive allosteric modulators at the GABA-A receptor, and the memory effect is mediated substantially through α1- and α5-containing receptor subtypes. The effect is on acquisition: memory already consolidated before the dose is intact, while new declarative memory formed afterward is impaired. That is why the term is anterograde amnesia, and why midazolam is given during procedures specifically to produce it. A drug used deliberately to stop people remembering a procedure is doing the same thing at bedtime.

The labeling reflects it. The temazepam label states under Warnings that “amnesia and other neuro-psychiatric symptoms may occur unpredictably.”

Which sleeping tablets are benzodiazepines

This is the single most useful thing on this page for a family reading a medication list, because these are usually prescribed as “a sleeping tablet” and the class is never mentioned.

Temazepam (Restoril), triazolam (Halcion), flurazepam (Dalmane), estazolam and quazepam (Doral) are all benzodiazepines. Everything on this page applies to them in full. If one of those names is on a list, the person is taking a benzodiazepine whether or not anyone has used the word.

Zolpidem, zaleplon and eszopiclone are not benzodiazepines. They act at the same receptor complex and carry their own amnestic effects — the FDA notes that patients experiencing complex sleep behaviors on these drugs “may not remember them” — but the evidence base is smaller and this site treats them separately. Z-drugs.

How much recovers after long-term use — the genuinely open question

Here the certainty ends, and the honest answer is: partly, slowly, and probably not completely.

A meta-analysis of long-term benzodiazepine users — averaging around ten years of use, range one to 34 years — found impairment across all twelve cognitive domains examined, with a mean weighted effect size of −0.74 and no confidence interval crossing zero. Its companion meta-analysis of what happens after withdrawal found that long-term users “do show recovery of function in many areas after withdrawal,” while “there remains a significant impairment in most areas of cognition” relative to controls — and that the data “did not support full restitution of function, at least in the first 6 months.”

The best age-appropriate trial randomized 104 long-term benzodiazepine hypnotic users aged 65 and over in UK general practice, double-blind and placebo-controlled. Sixty percent had taken them continuously for more than ten years; 27% for more than twenty. Eighty percent had successfully withdrawn at six months. Withdrawers showed relative improvement on several cognitive and psychomotor tasks at 24 or 52 weeks, and did not differ from continuers in sleep or withdrawal symptoms. The authors described the gains as “some subtle cognitive advantages” — their words, and worth keeping.

So: the impairment during use is certain. The removal of that impairment follows from stopping. The extent of recovery after years of use is uncertain, the timescale is six to twelve months rather than weeks, and nobody should promise a return to baseline.

References

1. Poly TN, Islam MM, Yang HC, Li YJ. Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020;87(3):241–249. PMID 31778821 · DOI 10.1016/j.jbspin.2019.11.003.
2. Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0174730. PMID 28448593 · DOI 10.1371/journal.pone.0174730.
3. Berry SD, Placide SG, Mostofsky E, et al. Antipsychotic and Benzodiazepine Drug Changes Affect Acute Falls Risk Differently in the Nursing Home. The Journals of Gerontology Series A. 2016;71(2):273–278. PMID 26248560 · DOI 10.1093/gerona/glv091.
4. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. PMID 16284208 · DOI 10.1136/bmj.38623.768588.47.
5. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age and Ageing. 2011;40(1):23–29. PMID 21068014 · DOI 10.1093/ageing/afq140.
6. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Safety. 2011;34(2):125–156. PMID 21247221 · DOI 10.2165/11539050-000000000-00000.
7. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205. PMID 25208536 · DOI 10.1136/bmj.g5205.
8. He Q, Chen X, Wu T, Li L, Fei X. Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies. Journal of Clinical Neurology. 2019;15(1):9–19. PMID 30375757 · DOI 10.3988/jcn.2019.15.1.9.
9. Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352:i90. PMID 26837813 · DOI 10.1136/bmj.i90.
10. Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case-Control Analysis. Drug Safety. 2015;38(10):909–919. PMID 26123874 · DOI 10.1007/s40264-015-0319-3.
11. Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. The American Journal of Psychiatry. 2020;177(6):497–505. PMID 32252539 · DOI 10.1176/appi.ajp.2019.19030315.
12. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136–142. PMID 25517224 · DOI 10.1001/jamapsychiatry.2014.1763.
13. Maust DT, Blow FC, Wiechers IR, Kales HC, Marcus SC. National Trends in Antidepressant, Benzodiazepine, and Other Sedative-Hypnotic Treatment of Older Adults in Psychiatric and Primary Care. The Journal of Clinical Psychiatry. 2017;78(4):e363–e371. PMID 28448697 · DOI 10.4088/JCP.16m10713.
14. Malagaris I, Mehta HB, Goodwin JS. Trends and variation in benzodiazepine use in nursing homes in the USA. European Journal of Clinical Pharmacology. 2022;78(3):489–496. PMID 34727210 · DOI 10.1007/s00228-021-03244-4.
15. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Internal Medicine. 2014;174(6):890–898. PMID 24733354 · DOI 10.1001/jamainternmed.2014.949.
16. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018;320(18):1889–1898. PMID 30422193 · DOI 10.1001/jama.2018.16131.
17. U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Drug Safety Communication, September 23, 2020. fda.gov. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class.
18. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician. 2018;64(5):339–351. PMID 29760253.
19. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125–133. PMID 27136449 · DOI 10.7326/M15-2175.
20. Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open. 2021;11(2):e035978. PMID 33568364 · DOI 10.1136/bmjopen-2019-035978.
21. Savić MM, Obradović DI, Ugrešić ND, Bokonjić DR. Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes. Neural Plasticity. 2005;12(4):289–298. PMID 16444900 · DOI 10.1155/NP.2005.289.
22. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37–48. PMID 14731058 · DOI 10.2165/00023210-200418010-00004.
23. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Archives of Clinical Neuropsychology. 2004;19(3):437–454. PMID 15033227 · DOI 10.1016/S0887-6177(03)00096-9.
24. Curran HV, Collins R, Fletcher S, Kee SCY, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychological Medicine. 2003;33(7):1223–1237. PMID 14580077 · DOI 10.1017/s0033291703008213.
25. O’Hara-Veintimilla K, Páez-García S, Ramirez-Triana J, Torres-Tello K, Verhelst-Forero P, Borda MG. Safety and effectiveness of strategies to deprescribe chronic benzodiazepine receptor agonist use in older adults: a systematic review. Age and Ageing. 2026;55(5):afag112. PMID 42089738 · DOI 10.1093/ageing/afag112.
26. SpecGx LLC. RESTORIL (temazepam) capsules — FDA-approved prescribing information (Warnings; Precautions; Geriatric Use). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc56f7fd-1aaf-48ff-8aa7-d467e59e1015.
27. U.S. Food and Drug Administration. Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. Drug Safety Communication, April 30, 2019. fda.gov. 2019. https://www.fda.gov/safety/medical-product-safety-information/certain-prescription-insomnia-medicines-new-boxed-warning-due-risk-serious-injuries-caused.

Bibliographic records on this page were retrieved from PubMed. Every reference links to its DOI or PubMed record.

Written and medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. Last reviewed August 21, 2026. This page is educational. DWARAA does not prescribe, deprescribe, diagnose or treat.